MetrioPharm Press Releases
-
Sven Zimmermann Joins MetrioPharm Management as CFO
MetrioPharm AG, welcomes Sven Zimmermann, as its new Chief Financial Officer, bringing more than a decade of experience in strategic transactions.
-
Last Patient Last Visit in MetrioPharm’s Phase II Clinical Trial in Psoriasis
MetrioPharm AG announces that the last patient was now examined during the currently ongoing clinical psoriasis Phase II study (Last Patient Last Visit).
-
MetrioPharm AG Publishes Annual Report for 2018
Financing round D for 20 million CHF was closed, Phase II clinical trial successfully initiated, Focus of the report: InflammAging.
-
MetrioPharm AG welcomes Barry Frankel as a new team member
He will be responsible for the future development strategy and Business Development. Negotiations with potential pharmaceutical partners will be a focus of his work.
-
MetrioPharm Enrolls Last Patient in Phase II Study on MP1032 in Psoriasis
MetrioPharm AG announces that it has enrolled the last patient with moderate-to-severe plaque psoriasis in its ongoing Phase II clinical trial.
-
Dr. Wolfgang Brysch, CEO of MetrioPharm AG, is a speaker on the panel Autoimmune and Inflammatory Diseases on February 25th
MetrioPharm AG announces that its CEO Dr. Wolfgang Brysch will participate in the 12th Annual European Life Science CEO Forum.
-
MetrioPharm AG Closes Financing Round of CHF 20 Million
MetrioPharm closes Private Equity Financing Round D. Funds to be used for ongoing Phase II study and a Phase IIa study in an additional indication.
-
MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to Canada
MetrioPharm AG announces that a substance patent for its lead compound MP1032 has been obtained in Canada. The Canadian patent CA 2791327 was granted on October 30, 2018.
-
MetrioPharm Announces Presentation of Preclinical Data on MP1032 in Multiple Sclerosis Therapy at ECTRIMS Congress 2018
MetrioPharm AG announces the presentation of preclinical data related to multiple sclerosis (MS) and the company’s lead-compound MP1032 at the 34th ECTRIMS Congress.
-
MetrioPharm Achieves 50% of Target Patients Randomized in MP1032 Phase II Clinical Trial
MetrioPharm AG, today announced that more than 50% of patients with moderate-to-severe psoriasis (PASI entry score 10-20) have been randomized in the company’s ongoing Phase II clinical trial.